NCT02370992

I125 Brachytherapy After TURP

Completed Last updated 19 August 2019

What this trial tests

trial testing I125 brachytherapy in Cancer in 3 participants. Completed in 1 July 2016.

Timeline

1 July 2011

Primary endpoint
1 July 2016

1 July 2016

Quick facts

Lead sponsor	The Leeds Teaching Hospitals NHS Trust
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3
Start date	1 July 2011
Primary completion	1 July 2016
Estimated completion	1 July 2016
Sites	1 location across United Kingdom

Drugs / interventions tested

• I125 brachytherapy

Conditions studied

• Cancer — all drugs for Cancer →

Sponsor

The Leeds Teaching Hospitals NHS Trust

Who can join

Adults 40 to 90, male only, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Low dose rate brachytherapy using iodine 125 is well established as a treatment for low and intermediate risk prostate cancer. Currently there is uncertainty as to the safety of this technique in patients who have had a previous transurethral resection of the prostate gland (TURP) for obstruction of the urine flow through the prostatic urethra. Early experience when the technique was being developed in the 1980s suggested that there was a higher incidence of urinary incontinence after brachytherapy if there had been a previous TURP. It is however clear that with increasing experience many centres offer this treatment to patients who have had previous TURP, using various parameters to select patients including time from the TURP and persence or absence of a significant cavity within the gland on MRI scanning. There has been no systematic study of I125 brachytherapy after TURP in the current era which might address and inform the practice for future patient. Hence this study is designed to formally assess the safety of I125 brachytherapy after previous TURP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.